Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
Immunovant (IMVT) Stock Price & Analysis
685 Followers
IMVT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.08 - $45.58
Previous Close$28.43
Volume1.23M
Average Volume (3M)1.16M
Market Cap
$4.11B
Enterprise Value$3.86B
Total Cash (Recent Filing)$269.93M
Total Debt (Recent Filing)$614.00K
Price to Earnings (P/E)-15.6
Beta0.98
Next Earnings
Jul 01, 2024EPS Estimate
-$0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.83
Shares Outstanding145,292,970
10 Day Avg. Volume1,099,293
30 Day Avg. Volume1,160,270
Standard Deviation0.24
R-Squared0.02
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)17.54
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-18.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-14.59
Forecast
1Y Price Target
$50.78Price Target Upside79.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Immunovant News
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageImmunovant may seize a larger share of the market due to a recent setback by a competitor, positioning its portfolio of FcRn inhibitors as a potential frontrunner in the treatment of myasthenia gravis.
Drug Development ProgressImmunovant's strategic plans are on track, with the company initiating 4-5 potentially pivotal programs aimed at addressing 10 indications, showcasing significant progress and potential for market growth.
Financial ForecastAnalysts are optimistic about Immunovant's financial future, setting a price target with a considerable upside potential based on the strong efficacy, safety, and broad application prospects of IMVT-1402.
Bears Say
Clinical Development RisksConcerns remain about potential safety issues with batoclimab compared to competitors, which could impact its competitiveness.
Competitive LandscapeA pipeline competitor is expected to report potentially competitive data, which could pose a risk to Immunovant's market position.
Financial StabilityImmunovant has a significant annual cash burn rate, which may impact its financial stability in the absence of additional funding or revenues.
---
Ownership Overview
58.53% Insiders
13.76% Mutual Funds
8.37% Other Institutional Investors
19.34% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $15.08 and its highest was $45.58 in the past 12 months.
What is Immunovant’s market cap?
Currently, no data Available
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Jul 01, 2024 which is in 73 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Feb 12, 2024. The company reported -$0.289 earnings per share for the quarter, beating the consensus estimate of -$0.432 by $0.143.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -$0.43.
How many shares outstanding does Immunovant have?
Immunovant has 145,292,970 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.289 in its last earnings report, beating expectations of -$0.432. Following the earnings report the stock price went up 3.352%.
Which hedge fund is a major shareholder of Immunovant?
Among the largest hedge funds holding Immunovant’s share is Perceptive Advisors LLC. It holds Immunovant’s shares valued at 98M.
---
Immunovant Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.78 (79.31% Upside)
$50.78 (79.31% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
83.77%
12-Months-Change
Fundamentals
Return on Equity
-44.51%
Trailing 12-Months
Asset Growth
55.94%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.
---
IMVT Stock 12 Months Forecast
Average Price Target
$50.78
▲(79.31% Upside)
Technical Analysis
Best Analysts Covering IMVT
1 Year
1 Year Success Rate
11/20 ratings generated profit
1 Year Average Return
+65.53%
reiterated a buy rating 2 months ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 55.00% of your transactions generating a profit, with an average return of +65.53% per trade.
---